Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin + CGM vs SMBG in T2DM (DP-DCT)
NCT07595289Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Aug 2026
- Primary completion
- Dec 2026
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Proportion of Participants Completing All DCT Procedures from Remote Informed Consent to Last Visit at 5 months, Reliability Evaluation at 24 months and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07595289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595289.